UK Markets closed

Sanofi (SAN.PA)

Paris - Paris Delayed price. Currency in EUR
Add to watchlist
83.87+1.57 (+1.91%)
At close: 5:37PM CEST
People also watch
Full screen
Previous close82.30
Bid71.12 x 1000
Ask71.74 x 44000
Day's range82.43 - 84.40
52-week range24.55 - 92.97
Avg. volume1,816,660
Market cap102.11B
PE ratio (TTM)11.70
EPS (TTM)7.17
Earnings date2 Nov 2017
Dividend & yield3.30 (3.40%)
Ex-dividend date2017-05-16
1y target est86.18
  • Alnylam/Sanofi's RNAi Drug Meets Endpoint in Study, Stock Up
    Zacks8 hours ago

    Alnylam/Sanofi's RNAi Drug Meets Endpoint in Study, Stock Up

    Alnylam (ALNY) and partner Sanofi RNAi therapeutic patisiran met its primary efficacy endpoint and all secondary endpoints in the phase III APOLLO study.

  • Is Sanofi (SNY) a Great Stock for Value Investors?
    Zacks9 hours ago

    Is Sanofi (SNY) a Great Stock for Value Investors?

    Let's see if Sanofi (SNY) stock is a good choice for value-oriented investors right now from multiple angles.

  • Reutersyesterday

    Sanofi tests three-in-one antibody to treat or prevent HIV

    A three-pronged man-made antibody, created by French drugmaker Sanofi and U.S. scientists, could offer a new way to treat or prevent HIV, following successful tests in monkeys. Plans are under way to try the so-called trispecific antibody in initial human trials before the end of 2018, potentially adding a new weapon in the fight against AIDS, assuming the product proves safe and effective. If all goes well, the three-in-one antibody could be used either as a long-acting treatment or a vaccine, according to Sanofi Chief Scientific Officer Gary Nabel.

By using Yahoo, you agree that we and our partners may use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more; Yahoo is now part of ‘Oath’ and a member of the Verizon family of companies. As of 15 September 2017, we plan to share some user information within our new family. Learn more